FDA panel greenlights broader access to six controversial peptides
TL;DR Summary
An FDA Pharmacy Compounding Advisory Committee voted to recommend loosening regulations on six peptide therapies—BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500—potentially enabling prescription-based access if the FDA approves; supporters hail a win for personalized medicine, but FDA scientists have warned there isn’t enough data on safety and efficacy, and a final decision could take months.
Topics:business#government-regulations#health#health-care-industry#pharmaceutical-industry-regulation#public-health#us-food-and-drug-administration
- FDA panel gives nod to six controversial peptides The Washington Post
- Opinion | The Peptide Wild West The New York Times
- FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next? ABC News - Breaking News, Latest News and Videos
- RFK Jr. promised to stop the ‘aggressive suppression’ of these controversial drugs. He’s making progress. Politico
- America Is About to Go Over a Peptide Cliff The Atlantic
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
16 min
vs 17 min read
Condensed
98%
3,278 → 55 words
Want the full story? Read the original article
Read on The Washington Post